Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | August 13, 2026 | August 14, 2026 |
| Zovio IncZVO · Entity 124041 | Director | August 31, 2022 | September 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 13, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 200,252 |
Ending reported balance
After 2026-08-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-13 · Sale · Disposed 50,000 · Balance 210,252 F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Row 2 · 2026-08-13 · Gift · Disposed 10,000 · Balance 200,252 F2: Represents a charitable donation of common stock to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
F2: Represents a charitable donation of common stock to a donor advised fund.
Zovio Inc
Report date August 31, 2022 · Filed September 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,865 |
Reported balance
After 2022-08-31 transaction · row 1
1 source rowRow 1 · 2022-08-31 · Exercise / conversion · Acquired 8,855 · Balance 71,865 F1: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,855 |
Reported balance
After 2022-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-31 · Exercise / conversion · Acquired 8,855 · Balance 8,855 F1: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock. F2: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock.
F2: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 14, 2026 20:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GiftClass A Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-057147 · wk-form4_1786739361.xml · nonDerivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,252 F2 · price: Represents a charitable donation of common stock to a donor advised fund. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 50,000 | $17.64 | $882,000.00 |
DisclosureSEC source: 0001628280-26-057147 · wk-form4_1786739361.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,252 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:24 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032911 · wk-form4_1778271857.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. F2 · derivative.expiration_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:24 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 34,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-032911 · wk-form4_1778271857.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:24 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 19,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032911 · wk-form4_1778271857.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,824 Underlying: Class A Common Stock · 19,824 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 32,000 | $9.23 | $295,360.00 |
DisclosureSEC source: 0001781149-25-000006 · wk-form4_1756412741.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,433 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 12, 2025 Filed May 13, 2025 20:42 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 50,000 | $7.59 | $379,500.00 |
DisclosureSEC source: 0001628280-25-025140 · wk-form4_1747168964.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,433 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.49 to $7.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2025 Filed May 8, 2025 23:01 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023991 · wk-form4_1746745306.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,819 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 05, 2025 Filed May 8, 2025 23:01 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023991 · wk-form4_1746745306.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. Read SEC document |
| May 05, 2025 Filed May 8, 2025 23:01 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 40,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-023991 · wk-form4_1746745306.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option · Derivative | 28,506 | $0.00 Strike: $4.76 | $0.00 |
DisclosureSEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 28,506 shares Expires 2029-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 17,058 | $8.38 | $142,946.04 |
DisclosureSEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · nonDerivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,175 F1 · shares: Reflects shares sold to cover the exercise price arising in connection with the exercise of the stock options. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,506 | $4.76 | $135,688.56 |
DisclosureSEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:43 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023252 · wk-form4_1715719371.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:43 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 76,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023252 · wk-form4_1715719371.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020735 · wk-form4_1715031108.xml · derivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028735 · doc4.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. F3 · derivative.expiration_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 80,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028735 · doc4.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028735 · doc4.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,453 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 21:29 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionRestricted Stock Units · Derivative | 8,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-017003 · doc1.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock. F1 · price: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. F2 · derivative.expiration_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 21:29 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionCommon Stock | 8,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-017003 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of Zovio, Inc. Common Stock. Read SEC document |
| May 09, 2022 Filed May 10, 2022 22:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 80,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028157 · doc4.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 08, 2022 Filed May 10, 2022 22:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028157 · doc4.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. F2 · derivative.expiration_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. Read SEC document |
| May 08, 2022 Filed May 10, 2022 22:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028157 · doc4.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:19 UTC | Zovio Inc ZVO · Entity 124041 | GrantRestricted Stock Unit · Derivative | 18,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007792 · doc1.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,890 Underlying: Common Stock · 18,890 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2023. F4 · derivative.expiration_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2023. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:19 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionRestricted Stock Unit · Derivative | 16,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007792 · doc1.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2022. F3 · derivative.expiration_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2022. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:19 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionCommon Stock | 16,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007792 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 29, 2022, 16,410 of the reporting person's restricted stock units were settled for an equal number of shares of the issuer's common stock. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:20 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionRestricted Stock Units · Derivative | 8,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-016660 · doc1.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,710 Underlying: Common Stock · 8,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. F3 · derivative.expiration_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:20 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionCommon Stock | 8,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-016660 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 31, 2021, 8,855 of the reporting person's restricted stock units were settled for an equal number of shares of the issuer's common stock. Read SEC document |
| May 06, 2021 Filed May 7, 2021 18:07 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030809 · doc4.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. F3 · derivative.expiration_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 18:07 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 46,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030809 · doc4.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 05, 2021 Filed May 7, 2021 18:07 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030809 · doc4.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,406 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 23:38 UTC | Zovio Inc ZVO · Entity 124041 | GrantRestricted Stock Unit · Derivative | 16,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007330 · doc1.xml · derivative · entry 3 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,410 Underlying: Common Stock · 16,410 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2022. F4 · derivative.expiration_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2022. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 23:38 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionRestricted Stock Unit · Derivative | 18,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007330 · doc1.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2021. F3 · derivative.expiration_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2021. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 23:38 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionCommon Stock | 18,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007330 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 29, 2021, 18,890 of the reporting person's restricted stock units were settled for an equal number of shares of the issuer's common stock. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 21:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 7,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064385 · doc4.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 7,522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On December 14, 2019, the reporting person was granted 7,522 restricted stock units vesting December 15, 2020. F2 · derivative.expiration_date: On December 14, 2019, the reporting person was granted 7,522 restricted stock units vesting December 15, 2020. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 21:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 7,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-064385 · doc4.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| September 08, 2020 Filed Sep 11, 2020 00:59 UTC | Zovio Inc ZVO · Entity 124041 | PurchaseCommon Stock | 10,000 | $4.26 | $42,579.00 |
DisclosureSEC source: 0001567619-20-016618 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,855 F1 · price: Represents the average share price of an aggregate total of 10,000 shares purchased in a price range of $4.02 to $4.52 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 23:53 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionRestricted Stock Units · Derivative | 8,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016258 · doc1.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,565 Underlying: Common Stock · 8,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. F3 · derivative.expiration_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 23:53 UTC | Zovio Inc ZVO · Entity 124041 | Exercise / conversionCommon Stock | 8,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-016258 · doc1.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 31, 2020, 8,855 of the reporting person's restricted stock units were settled for an equal number of shares of the issuer's common stock. Read SEC document |
| May 19, 2020 Filed May 19, 2020 15:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 10,000 | $4.40 | $44,000.00 |
DisclosureSEC source: 0001209191-20-030339 · doc4.xml · nonDerivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| May 12, 2020 Filed May 14, 2020 23:23 UTC | Zovio Inc ZVO · Entity 124041 | GrantRestricted Stock Unit · Derivative | 18,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-010197 · doc1.xml · derivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,890 Underlying: Common Stock · 18,890 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2021. F2 · derivative.expiration_date: Subject to the reporting person's continuing service, 100% of the restricted stock units shall vest on March 29, 2021. Read SEC document |
| May 05, 2020 Filed May 6, 2020 23:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012186 · doc4.xml · derivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,218 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| December 14, 2019 Filed Dec 17, 2019 22:43 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 7,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000144 · wf-form4_157662262254101.xml · derivative · entry 2 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,522 Underlying: Class A Common Stock · 7,522 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| December 14, 2019 Filed Dec 17, 2019 22:43 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,506 | $0.00 Strike: $4.76 | $0.00 |
DisclosureSEC source: 0001723128-19-000144 · wf-form4_157662262254101.xml · derivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,506 Underlying: Class A Common Stock · 28,506 shares Expires 2029-12-14 F1 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| August 31, 2019 Filed Jan 9, 2020 22:07 UTC | Zovio Inc ZVO · Entity 124041 | GrantRestricted Stock Unit · Derivative | 35,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-000819 · doc1.xml · derivative · entry 1 Kiely John · CIK 0001781149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,420 Underlying: Common Stock · 35,420 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. F2 · derivative.expiration_date: Subject to the reporting person's continuing service, the restricted stock units vest as follows: (i) 25% of the restricted stock units vest on the first anniversary of the vesting commencement date, and (ii) an additional 25% of the restricted stock units shall vest on each subsequent anniversary of the vesting commencement date. The vesting commencement date for the restricted stock units is August 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.